Galectin Therapeutics (GALT) Depreciation & Amortization (CF) (2010 - 2017)

Galectin Therapeutics' Depreciation & Amortization (CF) history runs 8 years deep, the most recent figure standing at $1000.0 for Q1 2017.

• In Q1 2017, Depreciation & Amortization (CF) changed 0.0% year-over-year to $1000.0; the TTM figure through Dec 2017 stood at $1000.0 (down 85.71% YoY), while the FY2017 annual figure was $1000.0, down 85.71% from the prior year.
• Depreciation & Amortization (CF) was $1000.0 for Q1 2017 at Galectin Therapeutics, down from $2000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $3000.0 in Q1 2013 to a low of $1000.0 in Q4 2015.
• Historically, Depreciation & Amortization (CF) has averaged $2176.5 across 5 years, with a median of $2000.0 in 2014.
• The sharpest annual moves came in 2013 and 2015: Depreciation & Amortization (CF) surged 200.0% in 2013, then sank 50.0% in 2015.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $3000.0 in 2013, then sank by 33.33% to $2000.0 in 2014, then tumbled by 50.0% to $1000.0 in 2015, then soared by 100.0% to $2000.0 in 2016, then tumbled by 50.0% to $1000.0 in 2017.
• The last three Depreciation & Amortization (CF) figures came in at $1000.0 (Q1 2017), $2000.0 (Q4 2016), and $2000.0 (Q3 2016), per Business Quant data.